SUBSCRIBE
SUBSCRIBE

GSK Bio

NEWS
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Sun Pharma Snaps Up GlaxoSmithKline’s Opiates Business
March 3, 2015
 · 
2 min read
Biowarfare Company Emergent's Cancer Spinoff Aptevo Therapeutics to Employ 70 - 90 in Seattle
Business
GlaxoSmithKline CEO’s Pay Cut by 46% as Profits Decline
February 27, 2015
 · 
4 min read
Business
GlaxoSmithKline Replaces Head of Struggling U.S. Operations
February 17, 2015
 · 
2 min read
The Pink Slip Valentine: Companies Making Job Cuts
Job Trends
The Pink Slip Valentine: Companies Making Job Cuts: Sanofi, InterMune, Abbott, Syngenta AG, GlaxoSmithKline, Amgen
February 13, 2015
 · 
12 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
GlaxoSmithKline Takes Full Control of GlycoVaxyn AG for $190 Million
February 11, 2015
 · 
2 min read
Job Trends
Jobs Chopped as GlaxoSmithKline to Shutter Montana Vaccine R&D Branch
February 6, 2015
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
GlaxoSmithKline Brings Three Banks on Board to Advise on Potential IPO
February 4, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
First Trial Finds GlaxoSmithKline Ebola Shot Safe
January 29, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
GlaxoSmithKline’s Long-Awaited Ebola Vaccine Due to Arrive in Liberia
January 23, 2015
 · 
3 min read
Load More
  • 2026 - Best Places to Work - Badge (1).png
JOBS
IN THE PRESS
Press Releases
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
May 28, 2025
 · 
9 min read
Press Releases
Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease
November 12, 2024
 · 
4 min read
Press Releases
Expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine approved in Canada for adults aged 50-59 at increased risk
November 5, 2024
 · 
7 min read
Press Releases
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
October 8, 2024
 · 
10 min read
Pharm Country
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
March 7, 2024
 · 
5 min read
Pharm Country
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
August 17, 2023
 · 
6 min read
Deals
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
May 16, 2023
 · 
7 min read
Business
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
December 2, 2022
 · 
5 min read